Clinical outcomes of coronavirus disease 2019 (COVID‐19) in cancer patients with prior exposure to immune checkpoint inhibitors
Qiuji Wu,
Qian Chu,
Hongyan Zhang,
Bin Yang,
Xudong He,
Yahua Zhong,
Xianglin Yuan,
Melvin L.K. Chua,
Conghua Xie
Affiliations
Qiuji Wu
Department of Radiation and Medical Oncology Zhongnan Hospital of Wuhan University Wuhan Hubei 430071 P. R. China
Qian Chu
Department of Oncology Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei 430030 P. R. China
Hongyan Zhang
Department of Radiation and Medical Oncology Zhongnan Hospital of Wuhan University Wuhan Hubei 430071 P. R. China
Bin Yang
Department of Medical Oncology Hubei Cancer Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei 430079 P. R. China
Xudong He
Department of Gastroenterology Dongfeng Hospital Hubei University of Medicine Shiyan Hubei 442000 P. R. China
Yahua Zhong
Department of Radiation and Medical Oncology Zhongnan Hospital of Wuhan University Wuhan Hubei 430071 P. R. China
Xianglin Yuan
Department of Oncology Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei 430030 P. R. China
Melvin L.K. Chua
Department of Radiation and Medical Oncology Zhongnan Hospital of Wuhan University Wuhan Hubei 430071 P. R. China
Conghua Xie
Department of Radiation and Medical Oncology Zhongnan Hospital of Wuhan University Wuhan Hubei 430071 P. R. China
